NCT03899467View on ClinicalTrials.gov

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

May 30, 2019

Primary Completion Date

March 31, 2022

Study Completion Date

September 19, 2022

Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
DRUG

GT0918

anti-tumor activity

Trial Locations (10)

10469

New York Cancer & Blood Specialists, The Bronx

11733

New York Cancer & Blood Specialists, East Setauket

21204

Chesapeake Urology Research Associates, Towson

29605

Greenville Health System, Greenville

30607

University Cancer & Blood Center, Athens

40202

Norton Cancer Institute, Louisville

44718

Gabrail Cancer Center Research, Canton

68130

G U Research Network, Omaha

75230

Mary Crowley Cancer Research, Dallas

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

All Listed Sponsors
lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY

NCT03899467 - The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC | Biotech Hunter | Biotech Hunter